Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Barchart · 3d ago

Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications

BIO-Europe provides a key platform to advance ongoing discussions and expand partnering opportunities across Artelo’s growing portfolio

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.